The emergence of multi-drug resistant and atypical pathogens has led to a rise in post-operative complications in the hospital (nosocomial) setting in a range of surgical procedures involving skin incisions. At times, the risk of such complications has reduced therapeutic options for trauma patients and wounded military personnel. NM-IL-12, as an immune stimulant, may work by a different mechanism than traditional antibiotics, and it is hoped that the drug will exhibit broad-spectrum activity against many bacterial, viral, fungal, and parasitic pathogens implicated in cutaneous infections by increasing location concentrations of Interferon Gamma. Neumedicines is planning to develop NM-IL-12 for use as a surgical incision infection anti-infective prophylactic agent. Its potential for this application has been documented by the accelerated closure of full-thickness wounds in mice by the mouse-version of IL-12 (called rMuIL-12). The safety of NM-IL-12 is being tested in healthy human volunteers.
If clinical trials show results similar to the effects observed in animal trials, it is hoped that the successful clinical development of NM-IL-12 for the treatment of battle and traumatic wounds could: